Price
No data yet.
Social Signal Score
Analyst Ratings
23 analystsRevenue
$256.46M+11390.14%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kenneth H. Galbraith
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 279
- Beta
- 1.17
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 0.72
Financials
Revenue
$256.46M+11390.1%Net Income
$173.70MEBITDA
$181.65MFree Cash Flow
$-24.11MEPS (diluted)
$2.28Shares Outstanding (diluted)
76.25M+284.4%Operating Expenses
$78.86MCash & Debt
$100.46MReturn of Capital
$11.99MRevenue by Segment (annual)
$40.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $105.97M | $-81.13M | $-1.08 |
| 2024 | $76.30M | $-122.69M | $-1.62 |
| 2023 | $76.01M | $-118.67M | $-1.72 |
| 2022 | $412.48M | $124.34M | $1.91 |
| 2021 | $26.68M | $-211.84M | $-4.06 |
| 2020 | $38.95M | $-180.55M | $-3.58 |
| 2019 | $29.54M | $-145.44M | $-3.83 |
| 2018 | $53.02M | $-36.56M | $-1.26 |
| 2017 | $51.76M | $-10.41M | $-0.49 |
| 2016 | $11.01M | $-33.81M | $-1.72 |
| 2015 | $9.66M | $-19.17M | $-0.97 |
| 2014 | $1.67M | $-12.94M | $-0.65 |
Valuation
ZYMEhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (14)
- Newsglobenewswire.com·3d ago·Neutral
Zymeworks Announces Participation in Upcoming Investor Conferences VANCOUVER, British Columbia, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced will participate in the following upcoming investor conferences:
View source ↗ - Newszacks.com·13d ago·Negative
Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates Zymeworks Inc. (ZYME) came out with quarterly earnings of $2.28 per share, missing the Zacks Consensus Estimate of $2.4 per share. This compares to a loss of $0.26 per share a year ago.
View source ↗ - Newsmarketbeat.com·26d ago·Negative
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside Zymeworks NASDAQ: ZYME outlined a partnering-focused research strategy, presented updated clinical data for its ZW191 antibody-drug conjugate in platinum-resistant ovarian cancer, and discussed its recently announced collaboration with Roche for the DLL3-targeting T-cell engager ZW209.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript Zymeworks Inc. (ZYME) Discusses Portfolio Strategy, Roche Partnership and Pipeline Updates Transcript
View source ↗ - Newsglobenewswire.com·29d ago·Negative
…e Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 VANCOUVER, British Columbia, Oct. 24, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRα-targeting antibody-drug conjugate (ADC),…
View source ↗ - Newsglobenewswire.com·30d ago·Negative
…on Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 VANCOUVER, British Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that it has entered into a global license and collaboration agreement with Roche for the research, development and commercialization of ZW209, a T cell engag…
View source ↗ - Newsglobenewswire.com·34d ago·Positive
…s Senior Vice President, Commercial and General Manager, Theravance Biopharma VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that Suzanne Monahan has been appointed Senior Vice President, Commercial and General Manager, Theravance Biopharma, effective immediately. Reporting directl…
View source ↗ - Newsglobenewswire.com·38d ago·Neutral
Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026 Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026
View source ↗ - Newsmarketbeat.com·51d ago·Negative
Zymeworks Completes Theravance Deal, Adds YUPELRI Cash Flow and Raises 2026 Outlook Zymeworks NASDAQ: ZYME said it has completed its acquisition of Theravance Biopharma, adding the COPD medicine YUPELRI, an acquired research portfolio, collaboration and royalty economics, Irish tax attributes and a commercial organization to its business.
View source ↗ - Newsseekingalpha.com·55d ago·Positive
Zymeworks Inc. (ZYME) M&A Call Transcript Zymeworks Inc. (ZYME) M&A Call Transcript
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
…nce and Final Transaction Details Following Theravance Biopharma Acquisition VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the final transaction details and updated financial guidance following the completion of its acquisition of Theravance Biopharma.
View source ↗ - Newsglobenewswire.com·60d ago·Neutral
Zymeworks Completes Acquisition of Theravance Biopharma VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today completed the previously announced acquisition of Theravance Biopharma. With the completion of the transaction, Theravance Biopharma is now part of Zymeworks, further advancing Zymeworks' s…
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Zymeworks Inc. (ZYME) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·87d ago·Negative
…. Zanidatamab's first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME's near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition.
View source ↗
Earnings
Mon, Mar 1(in 3 months)
Consensus estimate $0.13 per share
Typical surprise +0.4% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$2.28 vs $2.27beat
- Thu, Aug 6$-0.62 vs $-0.57miss
- Thu, May 7$-0.59 vs $-0.10miss
- Mon, Mar 2$-0.55 vs $-0.35miss
- Thu, Nov 6$-0.26 vs $-0.30beat
- Thu, Aug 7$0.03 vs $-0.52beat
Estimates and results for ZYME via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ZYME officers and directors.
- Bought
- —
- Sold
- $6.4m
0 trades
15 trades
- Platshon Scottsold
- Moore Paul Andrewsold
- Moore Paul Andrewsold
- Moore Paul Andrewsold
- Schayowitz Adamsold
- Hollywood Marksold
- Smith Jeffrey T Lsold
- Moore Paul Andrewsold
85 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ZYME.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
